Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT07098897

PHASE3

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Sponsor: The Affiliated Hospital of Xuzhou Medical University

View on ClinicalTrials.gov

Summary

The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Telitacicept in patients with IgA nephropathy. The control group will be observed for up to 6months without administration of Telitacicept. This Single center, Randomized, Open Label, Comparative study will evaluate the effect and safety of and Standard treatment for 6months in IgA Nephropathy.

Official title: To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy, Single Center, Randomized, Open Label, Comparative Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2024-08-01

Completion Date

2025-09-30

Last Updated

2025-08-01

Healthy Volunteers

Conditions

IgA Nephropathy (IgAN)

Interventions

DRUG

Telitacicept 160mg

Currently monoclonal antibodies, that may affect the main axis of pathogenesis of IgA nephropathy and biological therapy such as Telitacicept, provides a new treatment option and altering or depletion or modulation of Gd-IgA1 producing B cells and plasma cells. At present, Telitacicept are used for clinical treatment in IgA nephropathy patient inside China, but still clear data on safety and effect, and patient's complete remission, repeated relapse data are unclear.

DRUG

Corticosteroid

Standard Supportive Care plus Corticosteroid(≤1mg/kg/d) without immunosuppressants

DRUG

ACE Inhibitor or Angiotensin receptor antagonist

Drug: ACE Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization Drug: ARB Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization

Inclusion Criteria: * Age 18\~75 years, regardless of gender. * Clinical evaluation and renal biopsy diagnostic for IgA nephropathy. * Average urinary protein excretion of 0.3\~3.5g/24h on two successive examinations. * Urine Protein to Creatinine Ratio (UPCR) \>= 0.75 and \<= 6 milligram per milligram (mg/mg) during screening. * Stable and optimal dose of Angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blockers (ARB) at least 8 weeks prior to screening. * eGFR≥30 ml/min/1.73m2. * Willingness to sign an informed consent. Exclusion Criteria: * • Secondary IgA nephropathy such as systemic lupus erythematosus, Henoch-Schonlein purpuric nephritis and hepatitis B-associated nephritis, etc. * IgA nephropathy with significant glomerulosclerosis or cortical scarring. * Failure to meet estimated glomerular filtration rate (eGFR) and biopsy requirement criteria. * Rapidly progressive nephritic syndrome. * Acute renal failure, including rapidly progressive IgA nephropathy. * Current or recent (within 30 days) exposure to high-dose of steroids or immunosuppressive therapy (CTX、MMF、CsA、FK506). * Cirrhosis, chronic active liver disease, and serious liver function damage. * History of significant gastrointestinal disorders (e.g. severe chronic diarrhea or active peptic ulcer disease). * Any Active systemic infection or history of serious infection within one month. * Other major organ system disease (e.g. serious cardiovascular diseases including congestive heart failure, chronic obstructive pulmonary disease, asthma requiring oral steroid treatment or central nervous system diseases). * Active tuberculosis or untreated latent TB infection. * Malignant hypertension that is difficult to be controlled by oral drugs. * Known allergy, contraindication, or intolerance to the steroids. * Pregnancy or breast feeding at the time of entry or unwillingness to comply with measures for contraception. * Malignant tumors. * Excessive drinking or drug abuse. * Mental aberrations. * Any condition, including any uncontrolled disease state other than IgA nephropathy.

Locations (1)

The First Affiliated hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Clinical Research Directory

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (1)